Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 30, Number 4—April 2024
Research Letter

Opportunistic Elizabethkingia miricola Infections in Intensive Care Unit, Spain

Author affiliations: Hospital Universitario San Cecilio, Granada, Spain (E. Soler-Iborte, M. Rivera-Izquierdo, C. Valero-Ubierna); Instituto biosanitario de Granada, Granada, (M. Rivera-Izquierdo); Ciber de Epidemiología y Salud Pública, Madrid, Spain (M. Rivera-Izquierdo)

Cite This Article

Abstract

In 2021, we identified a cluster of Elizabethkingia miricola cases in an intensive care unit in Spain. Because E. miricola is not considered a special surveillance agent in Spain, whole-genome sequencing was not performed. The bacterial source was not identified. All Elizabethkingia species should be listed as special surveillance bacteria.

The Elizabethkingia genus is formed by a group of gram-negative, aerobic, and nonfermenting bacteria widely distributed in nature and environments, such as water and hospital taps (1). In 2003, a new a bacterial species was identified in the condensation water obtained from the Mir space station in 1997 and was assigned as Chryseobacterium miricola (2). That new species was later transferred to the Elizabethkingia genus and renamed Elizabethkingia miricola (3). This species is considered as an uncommon low-pathogenic agent in clinical samples, acting as an opportunistic pathogen, but since 2008, it has become an emerging bacterium of increasing relevance (4). E. miricola has not been fully epidemiologically characterized but is considered intrinsically resistant to multiple drugs (5).

We describe a cluster of E. miricola in the intensive care unit (ICU) of the Hospital Universitario San Cecilio in Granada, Spain. The index case corresponded to a 66-year-old man hospitalized for COVID-19. The microbiology service identified E. miricola isolates from a bronchial aspirate sample by using matrix-assisted laser desorption/ionization time-of-flight mass spectrometry and informed the ICU of a positive result on March 19, 2021. Two days later, a 70-year-old man hospitalized in the same unit for COVID-19 also tested positive for E. miricola in a bronchial aspirate sample sent for a previous diagnosis with tracheobronchitis associated with Stenotrophomonas maltophilia.

Throughout 2021, we found 13 more cases of E. miricola in the same ICU. Given the identification of the same species, and for clinical and epidemiologic criteria, the outbreak was considered nosocomial. However, although isolates were retained for potential future research, no whole-genome sequencing could be performed because the species is not included as special surveillance agent for the Andalusian Health System because of resource limitations. The reason for admission in 11 (73.3%) patients was COVID-19. Of the 15 case-patients, 11 (73.3%) were men and 4 (26.7%) women, 6 (40.0%) had tracheobronchitis diagnoses, 3 (20.0%) had ventilator-associated pneumonia, and 1 (6.7%) had catheter-related bacteremia; 8 (53.3%) patients died (Table).

All patients received steroid treatment during their ICU stays. All case-patients were intubated during their hospitalization. The average length of ICU stay was 43.8 days, and the length between admission and identification of the agent was long, a mean of 26.4 days.

Because 290 days elapsed from identification of the index case (March 19) to identification of the last case (December 30), we assumed persistence of the agent in the ICU environment. Nevertheless, despite a search of environmental and surface samples, the definitive focus of persistence was not identified. Because of possible cross-transmission in a unit with such vulnerable patients, we notified the Service of Preventive Medicine and Public Health, which initiated prevention measures. Because of the lack of available knowledge related to E. miricola and closely related species, we reinforced standard precautions and established contact precautions. Finally, by December 2021, we conducted a thorough disinfection of all surfaces in the ICU, after which no more cases were identified.

In other countries, cases of multidrug resistance were identified in the context of antimicrobial drug pressure and cases of sepsis and pneumonia were diagnosed among immunosuppressed patients (5). In our hospital, 8 (53.3%) patients died. The average time from bacterial isolation to death was 18.2 (range 2–65) days.

Elisabethkingia isolates are usually resistant to multiple antibiotics. In analyses of different isolates collected in South Korea and Taiwan (5), all E. miricola isolates were resistant to cephalosporins, aminoglycosides, and carbapenems. Those data are similar to results obtained in our hospital (Table). A study conducted in Switzerland found genes encoding metallo-β-lactamases in a multidrug-resistant E. miricola isolated from the urine of a 2-year-old boy (6). Those genes provide resistance to penicillin-β-lactamase inhibitor combinations, carbapenems, cefotaxime, and cefoxitin. Trimethoprim/sulfamethoxazole showed the best antibiogram sensitivity in our outbreak, only 1 of 15 patients showed resistance (Table).

In summary, our study underlines the need to find Elizabethkingia spp. bacteria in ICUs. In addition, all species in the Elizabethkingia genus should be listed as special surveillance bacteria due to their capacity to cause major illness and death in vulnerable patients. Future studies analyzing differences in the outcomes between patients with E. miricola and other patients admitted to ICU, including patient characteristics and treatments, could expand on the information provided in this study. Finally, to enable early detection of outbreaks of intrinsically antimicrobial-resistant bacteria, modify patient treatment, and save lives, whole-genome sequencing needs to be instituted when rare agents not previously considered for special surveillance are identified.

Dr. Soler-Iborte is a preventive medicine and public health resident at Hospital Universitario San Cecilio, Granada, Spain. Her research interests include nosocomial infections, vaccines, epidemiology and infectious disease prevention in the hospital setting.

Top

Acknowledgment

E.S.-I. and C.V.-U. participated in the treatment and preventive measures for controlling the outbreak. M.R.-I. supervised the work. All authors participated in writing and revising the manuscript for intellectual content.

Top

References

  1. Zdziarski  P, Paściak  M, Rogala  K, Korzeniowska-Kowal  A, Gamian  A. Elizabethkingia miricola as an opportunistic oral pathogen associated with superinfectious complications in humoral immunodeficiency: a case report. BMC Infect Dis. 2017;17:763. DOIPubMedGoogle Scholar
  2. Li  Y, Kawamura  Y, Fujiwara  N, Naka  T, Liu  H, Huang  X, et al. Chryseobacterium miricola sp. nov., a novel species isolated from condensation water of space station Mir. Syst Appl Microbiol. 2003;26:5238. DOIPubMedGoogle Scholar
  3. Kim  KK, Kim  MK, Lim  JH, Park  HY, Lee  ST. Transfer of Chryseobacterium meningosepticum and Chryseobacterium miricola to Elizabethkingia gen. nov. as Elizabethkingia meningoseptica comb. nov. and Elizabethkingia miricola comb. nov. Int J Syst Evol Microbiol. 2005;55:128793. DOIPubMedGoogle Scholar
  4. Gupta  P, Zaman  K, Mohan  B, Taneja  N. Elizabethkingia miricola: A rare non-fermenter causing urinary tract infection. World J Clin Cases. 2017;5:18790. DOIPubMedGoogle Scholar
  5. Lin  JN, Lai  CH, Yang  CH, Huang  YH. Elizabethkingia infections in humans: from genomics to clinics. Microorganisms. 2019;7:295. DOIPubMedGoogle Scholar
  6. Colapietro  M, Endimiani  A, Sabatini  A, Marcoccia  F, Celenza  G, Segatore  B, et al. BlaB-15, a new BlaB metallo-β-lactamase variant found in an Elizabethkingia miricola clinical isolate. Diagn Microbiol Infect Dis. 2016;85:1957. DOIPubMedGoogle Scholar

Top

Table

Top

Cite This Article

DOI: 10.3201/eid3004.231491

Original Publication Date: March 18, 2024

Table of Contents – Volume 30, Number 4—April 2024

EID Search Options
presentation_01 Advanced Article Search – Search articles by author and/or keyword.
presentation_01 Articles by Country Search – Search articles by the topic country.
presentation_01 Article Type Search – Search articles by article type and issue.

Top

Comments

Please use the form below to submit correspondence to the authors or contact them at the following address:

Address for correspondence. Eva Soler-Iborte, Service of Preventive Medicine and Public Health, Hospital Universitario San Cecilio, Avenida del Conocimiento s/n 18016, Granada, Spain

Send To

10000 character(s) remaining.

Top

Page created: February 23, 2024
Page updated: March 21, 2024
Page reviewed: March 21, 2024
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external